Tech Company Financing Transactions
Envisia Therapeutics Funding Round
On 11/13/2013, Envisia Therapeutics raised $25 million in Series A funding from Canaan Partners, Morningside Group and New Enterprise Associates.
Transaction Overview
Company Name
Announced On
11/13/2013
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series A
Proceeds Purpose
The money will be used to advance ENV515 and other undisclosed follow-on programs to critical R&D milestones.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
P.O. Box 110065
Research Triangle Park, NC 27709
USA
Research Triangle Park, NC 27709
USA
Phone
Website
Email Address
Overview
As many as 285 million people suffer from disease-related visual impairments and blindness,1 but an estimated 80 percent of these visual impairments are actually preventable2.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Eric Linsley
President
Benjamin Yerxa
VP - Bus. Development
Tomas Navratil
Browse more venture capital transactions:
Prev: 11/13/2013: Maxta venture capital transaction
Next: 11/13/2013: Legend3D venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs